Literature DB >> 23868823

Serum proteomics in amnestic mild cognitive impairment.

Linda Ijsselstijn1, Janne M Papma, Lennard J M Dekker, Wim Calame, Christoph Stingl, Peter J Koudstaal, Niels D Prins, Peter A E Sillevis Smitt, Theo M Luider.   

Abstract

We have explored proteins related to mild cognitive impairment (MCI). The serum proteome of 35 amnestic MCI patients and 35 cognitively healthy persons was investigated by LC MS. We identified 108 differentially expressed peptides between MCI patients and controls, belonging to 39 proteins. Eight proteins were selected for further investigation by quantitative protein measurements using a MRM assay; apolipoprotein E, carboxypeptidase N subunit 2, complement factor B (CFAB), galectin-3 binding protein (LG3BP), lumican, serum amyloid A-4 protein (SAA4), serum amyloid P-component, and sex hormone binding globulin. Results of the quantitative protein measurements showed significantly decreased levels of carboxypeptidase N subunit 2, CFAB, LG3BP, SAA4, and serum amyloid P-component in serum from amnestic MCI patients compared with cognitive healthy controls (two-sided t-test; p < 0.05). Apolipoprotein E and lumican showed no significant difference in protein levels, sex hormone binding globulin could not be quantified since the MRM assay did not reach the required sensitivity. A model based on the three most significantly decreased proteins (CFAB, LG3BP, and SAA4) showed a sensitivity and specificity of 73 and 66%, respectively, for the initial sample set. A small external validation set yielded 77% sensitivity and 75% specificity.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Amnestic; Biomedicine; MCI; Serum

Mesh:

Substances:

Year:  2013        PMID: 23868823     DOI: 10.1002/pmic.201200190

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  7 in total

Review 1.  Unbiased and targeted mass spectrometry for the HDL proteome.

Authors:  Sasha A Singh; Masanori Aikawa
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

Review 2.  The Potential of 'Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer's Disease in African Americans.

Authors:  Kaitlyn E Stepler; Renã A S Robinson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  Association of plasma apolipoproteins and levels of inflammation-related factors with different stages of Alzheimer's disease: a cross-sectional study.

Authors:  Ting Wang; Xiaoni Wang; Yunxia Yao; Chunsong Zhao; Caixia Yang; Ying Han; Yanning Cai
Journal:  BMJ Open       Date:  2022-04-06       Impact factor: 2.692

Review 4.  Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration.

Authors:  Juan García-Revilla; Antonio Boza-Serrano; Ana M Espinosa-Oliva; Manuel Sarmiento Soto; Tomas Deierborg; Rocío Ruiz; Rocío M de Pablos; Miguel Angel Burguillos; Jose L Venero
Journal:  Cell Death Dis       Date:  2022-07-20       Impact factor: 9.685

5.  Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.

Authors:  Anand Venkatraman; Peter Callas; Leslie A McClure; Fred Unverzagt; Garima Arora; Virginia Howard; Virginia G Wadley; Mary Cushman; Pankaj Arora
Journal:  Alzheimers Dement (N Y)       Date:  2018-04-26

6.  Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level.

Authors:  Shizhan Ma; Shangbin Li; Renjun Lv; Xunyao Hou; Shanjing Nie; Qingqing Yin
Journal:  J Diabetes Investig       Date:  2020-04-28       Impact factor: 4.232

7.  Investigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseases.

Authors:  Júlia Costa; Ana Pronto-Laborinho; Susana Pinto; Marta Gromicho; Sara Bonucci; Erin Tranfield; Catarina Correia; Bruno M Alexandre; Mamede de Carvalho
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.